To realize the first-mover’s advantage and maximize the market uptake, pharmaceutical companies are hard at work to significantly reduce product development cycles. Among all the initiatives that are often considered for an accelerated timeline, implementation of digital technologies has witnessed a surge over the past few years. A robust digital foundation not only helps with faster product delivery, but also significantly reduces financial burdens. While digital technologies include a wide variety of tools, herein, we turn our attention to the application of “mechanistic modeling” in bioprocesses. It is widely accepted that among all the modeling strategies for bioprocesses, “mechanistic modeling” and the use of first principles is a first go.<br/>            A quick glance at a typical process for the development of biotherapeutics reveals that the existence of fluid flow is a common factor among all the unit operations. Therefore, an in-depth understanding of hydrodynamics is key for bioprocess development. To achieve this, first principle mathematical approaches can provide a reliable path to understanding fluid flow mechanics. Additionally, first principle mechanistic models can often be coupled to allow for the inclusion of multiple biophysical/biochemical phenomena and the generation of a holistic modeling strategy for a specific unit operation. In this presentation, we share some applications of mechanistic/hybrid modeling in bioprocess development and scale up.

Applications of mechanistic/hybrid modeling in bioprocess development and scale up

ACS Fall 2021

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.